3452 results about "Polymeric matrix" patented technology

A coating composition is disclosed which comprises an aqueous polymeric matrix, a hydrophilic polymer, a colloidal metal oxide and a crosslinker. The coating composition when applied on medical devices is hydrophilic, shows improved lubricity, abrasion resistance and substrate adhesion on metallic or plastic substrates. The coating also shows improved water sheeting thus providing the coated substrates with anti-fog properties. The coating absorbs aqueous dye or stain solutions making the substrate suitable for printing.

In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful election of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a redispersible dry powder comprising nanoparticles of water-insoluble drug coated with a protein, and free protein to which molecules of the pharmacological agent are bound. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable (in the form of molecules bound to the protein), and part of the agent is present within particles without any polymeric matrix therein.

A porous polymeric matrix containing at least one natural polymer and at least one synthetic polymer and optionally at least one cation. Furthermore, a method of making a porous polymeric matrix involving mixing at least one natural polymer and inorganic salts with a solution comprising at least one solvent and at least one synthetic polymer to form a slurry, casting the slurry in a mold and removing the solvent to form solid matrices, immersing the solid matrices in deionized water to allow natural polymer cross-linking and pore creation to occur simultaneously, and drying the matrices to create a porous polymeric matrix; wherein the matrix contains a cation. Also, a method of making a porous polymeric matrix, involving mixing at least one natural polymer in an aqueous solvent and mixing at least one synthetic polymer in an organic solvent, combining the mixtures and casting in a mold, and separately removing said aqueous solvent and said organic solvent to form a porous polymeric matrix; wherein the porous polymeric matrix does not contain a cation.

Devices suitable for implantation in a body of a host and systems and methods for their manufacture are provided. The implantable devices include a composite material formed at least from a matrix material and hollow gas-filled beads. In preferred embodiments, the composite material includes a polymeric matrix mixed with hollow air-filled glass beads, which are mixed and cured to form at least a portion of the body of the implantable device. Implantable devices including this composite material have decreased weight and/or overall density as compared to implantable devices without the beads incorporated therein, which is believed to improve the acceptance and function of the implantable device in vivo. Additionally, implantable devices concerned with transmitting and receiving via RF are believed to achieve improved RF performance due to a reduced dielectric constant provided by the incorporation of beads within the composite material.

The invention relates to a preparation method of a polymer/graphene composite material through in situ reduction, which is characterized by comprising the following steps: adopting ultrasonic wave or grinding to evenly disperse the graphite oxide prepared by a Hummers method into polymer dispersion; introducing reducing agent into the polymer dispersion for in situ reduction, enabling the graphite oxide to be reduced into the grapheme so as to obtain stable polymer/graphene composite emulsion; carrying out demulsification, agglomeration and drying to obtain the composite polymer/grapheme composite master batch; adding the dried polymer/grapheme composite master batch and various assistants into the polymeric matrix according to a certain ratio; and carrying out double-roller mixing, vulcanization, melt extrusion or injection molding to obtain the polymer/graphene composite material with excellent physical and mechanical properties.

A wet shaving system is disclosed including a blade member and a skin-engaging portion in proximity to said blade member, the skin-engaging portion comprising a solid polymeric shaving aid composite including an exposed portion containing a water-soluble shaving aid dispersed in a water-insoluble polymeric matrix, the water soluble shaving aid being coated with mineral oil.

The present invention generally encompasses a medical article, such as a medical device or coating comprising an agent or combination of agents, wherein the agent is distributed throughout a polymeric matrix. The polymeric matrix comprises an agent and a poly(ester amide) having a design that was preselected to provide a predetermined release rate of the combination of agents from the medical article.

Oilfield elements and assemblies are described comprising a polymeric matrix formed into an oilfield element, and a plurality of expanded graphitic nanoflakes and/or nanoplatelets dispersed in the polymeric matrix. Methods of using the oilfield elements and assemblies including same in oilfield operations are also described. This abstract allows a searcher or other reader to quickly ascertain the subject matter of the disclosure. It will not be used to interpret or limit the scope or meaning of the claims. 37 CFR 1.72(b).

This invention is directed toward surface treatment of a device. The surface treatment comprises the attachment of terminal functionalized surfactants to the surface of the substrate by means of reactive functionalities of the terminal functionalized surfactant material reacting with complementary surface reactive functionalities in monomeric units along the polymer substrate. The present invention is also directed to a surface modified medical device, examples of which include contact lenses, intraocular lenses, vascular stents, phakic intraocular lenses, aphakic intraocular lenses, corneal implants, catheters, implants, and the like, comprising a surface made by such a method.

Compositions are provided comprising a lipophilic active compound, e.g., a human or veterinary drug or a nutraceutical, interwoven with a polymeric matrix formed by two or more polymers, wherein one of the polymers is an amphiphilic polymer and the other polymer is either an amphiphilic polymer with a different hydrophobic-hydrophilic balance or a hydrophilic polymer, and the active lipophilic compound has modified physicochemical properties. The composition forms colloidal nanodispersion upon contact with aqueous media.

Extravascular implantable medical devices are described. The devices include a polymeric layer comprising a polymeric matrix and pores. Therapeutic agent is loaded in the matrix, in the pores, or in the matrix and the pores. The devices include a structural surface layer. Additional therapeutic agent may be loaded in or on the surface layer. The devices may also include one or more intermediate layer, into or onto which additional therapeutic agent may be loaded.

Compositions including fibers, fillers, reinforcing agents or other property-enhancing agents added to a polymeric matrix formed from DCPD monomer or related compounds such as norbornene and norbornadiene are disclosed. The composition has a mechanically forgiving matrix due to the polymer with the inherent strength and other physical properties of the enhancement agent according to the invention. Enhancement agents according to the invention generally include inorganic, organic and metallic substances in a variety of forms.

The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.

The invention relates to a composite comprising a weight fraction of single-wall carbon nanotubes and at least one polar polymer wherein the composite has an electrical and/or thermal conductivity enhanced over that of the polymer alone. The invention also comprises a method for making this polymer composition. The present application provides composite compositions that, over a wide range of single-wall carbon nanotube loading, have electrical conductivities exceeding those known in the art by more than one order of magnitude. The electrical conductivity enhancement depends on the weight fraction (F) of the single-wall carbon nanotubes in the composite. The electrical conductivity of the composite of this invention is at least 5 Siemens per centimeter (S/cm) at (F) of 0.5 (i.e. where single-wall carbon nanotube loading weight represents half of the total composite weight), at least 1 S/cm at a F of 0.1, at least 1×10^{−4 S/cm at (F) of 0.004, at least 6×10−9} S/cm at (F) of 0.001 and at least 3×10⁻¹⁶ S/cm (F) plus the intrinsic conductivity of the polymer matrix material at of 0.0001. The thermal conductivity enhancement is in excess of 1 Watt/m-° K. The polar polymer can be polycarbonate, poly(acrylic acid), poly(acrylic acid), poly(methacrylic acid), polyoxide, polysulfide, polysulfone, polyamides, polyester, polyurethane, polyimide, poly(vinyl acetate), poly(vinyl alcohol), poly(vinyl chloride), poly(vinyl pyridine), poly(vinyl pyrrolidone), copolymers thereof and combinations thereof. The composite can further comprise a nonpolar polymer, such as, a polyolefin polymer, polyethylene, polypropylene, polybutene, polyisobutene, polyisoprene, polystyrene, copolymers thereof and combinations thereof.

The present invention includes methods and materials for soft tissue implant formed from biologically-compatible polymeric matrixes. The matrixes may have pores sized for in-growth of soft tissue. The material may be utilized with collagen or other matrix materials. This material may be used in a method of reforming soft tissues by implanting the material within soft body tissues to modify soft tissue defects such as wrinkles or biopsy tissue defects and to reshape soft tissue.

A zero-order sustained-release delivery system for delivery of carbamazepine or a derivative thereof. A polymeric matrix formulation of carbamazepine comprises hydrophilic polymer or hydrophilic/hydropholic polymer mixture which permits carbamazepine or carbamezepine derivative to be released from the polymer matrix in zero-order release kinetics.

An oral delivery system for Class II drugs that have low oral bioavailability due to their insolubility in water and slow dissolution kinetics and method for making such a drug delivery system are disclosed herein. The formulation may be a controlled release or immediate release formulation. The immediate release formulation contains a Class II drug, together with a hydrophobic polymer, preferably a bioadhesive polymer. In one embodiment, the drug and polymer are co-dissolved in a common solvent. The solution is formed into small solid particles by any convenient method, particularly by spray drying. The resulting particles contain drug dispersed as small particles in a polymeric matrix. The particles are stable against aggregation, and can be put into capsules or tableted for administration. The controlled release formulations contain a BCS Class II drug and a bioadhesive polymer. The controlled release formulations may be in the form of a tablet, capsules, mini-tab, microparticulate, or osmotic pump. Enhancement of oral uptake of the drug from use of bioadhesive polymers occurs through (1) increased dissolution kinetics due to stable micronization of the drug, (2) rapid release of the drug from the polymer in the GI tract; and (3) prolonged GI transit due to bioadhesive properties of the polymers. The combination of these effects allows the preparation of a compact, stable dosage form suitable for oral administration of many class II drugs.

The invention relates to synthetic, bioabsorbable polymer materials and implants, like fibres, sutures, meshes and other tissue management, wound closure or tissue engineering devices, which contain: a) a bioabsorbable polymeric matrix; b) antibiotic and/or anti-inflammatory agent particles or mixture thereof, dispersed in the matrix, and c) optionally an additive agent to facilitate device recognition and/or handling to facilitate the use and application of finalized product. In the matrix, cavities around the particles are induced by mechanical processing of the matrix phase. A preferred embodiment of the present invention is a device (suture) that provides a sustained release of antibiotic agent over several days to several weeks for the prevention or treatment of infection. The sutures may be effectively implanted into or in the vicinity of: 1) infected tissue, 2) potentially infected tissue, or in tissues where infection, should it occur, leads to disastrous consequences.